These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38616460)

  • 1. A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study.
    Sharp ASP; Kandzari DE; Townsend RR; Kario K; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Böhm M; Choi JW; Liu M; DeBruin V; Lee DP
    Cardiovasc Revasc Med; 2024 Apr; ():. PubMed ID: 38616460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial.
    Wang J; Yin Y; Lu C; Lu Z; Hu J; Wang Y; Ge J; Jiang H; Yao C; Yan X; Ma W; Qi X; Dang Y; Chen S; Zhu J; Wang D; Ding C; Wang W; Liu J; Wang Y; Li H; Pan Z; Cui K; Li C; Liang X; Chen W; Sobotka PA; Zhang J; Esler M; Sun N; Chen M; Huo Y
    EClinicalMedicine; 2024 Jun; 72():102626. PubMed ID: 38756107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design.
    Böhm M; Townsend RR; Kario K; Kandzari D; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Hickey GL; Fahy M; DeBruin V; Brar S; Pocock S
    Clin Res Cardiol; 2020 Mar; 109(3):289-302. PubMed ID: 32034481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.
    Böhm M; Mahfoud F; Townsend RR; Kandzari DE; Pocock S; Ukena C; Weber MA; Hoshide S; Patel M; Tyson CC; Weil J; Agdirlioglu T; Fahy M; Kario K
    Eur Heart J; 2019 Mar; 40(9):743-751. PubMed ID: 30608521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.
    Townsend RR; Ferdinand KC; Kandzari DE; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; David S; Steigerwalt S; Walton A; Hopper I; Bertolet B; Sharif F; Fengler K; Fahy M; Hettrick DA; Brar S; Böhm M
    Hypertension; 2024 May; 81(5):1095-1105. PubMed ID: 38314554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.
    Kandzari DE; Townsend RR; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; Konstantinidis D; Choi J; East C; Lauder L; Cohen DL; Kobayashi T; Schmid A; Lee DP; Ma A; Weil J; Agdirlioglu T; Schlaich MP; Shetty S; Devireddy CM; Lea J; Aoki J; Sharp ASP; Anderson R; Fahy M; DeBruin V; Brar S; Böhm M;
    J Am Coll Cardiol; 2023 Nov; 82(19):1809-1823. PubMed ID: 37914510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA; Mahfoud F; Schmieder RE; Kandzari DE; Tsioufis KP; Townsend RR; Kario K; Böhm M; Sharp ASP; Davies JE; Osborn JW; Fink GD; Euler DE; Cohen DL; Schlaich MP; Esler MD
    JACC Cardiovasc Interv; 2019 Jun; 12(12):1095-1105. PubMed ID: 31221299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K;
    Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.
    Böhm M; Tsioufis K; Kandzari DE; Kario K; Weber MA; Schmieder RE; Townsend RR; Kulenthiran S; Ukena C; Pocock S; Ewen S; Weil J; Fahy M; Mahfoud F
    J Am Coll Cardiol; 2021 Sep; 78(10):1028-1038. PubMed ID: 34474735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial.
    Weber MA; Schmieder RE; Kandzari DE; Townsend RR; Mahfoud F; Tsioufis K; Kario K; Pocock S; Tatakis F; Ewen S; Choi JW; East C; Lee DP; Ma A; Cohen DL; Wilensky R; Devireddy CM; Lea JP; Schmid A; Fahy M; Böhm M
    Clin Res Cardiol; 2022 Nov; 111(11):1269-1275. PubMed ID: 35852582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan).
    Lee CK; Wang TD; Lee YH; Fahy M; Lee CH; Sung SH; Kao HL; Wu YW; Lin TH
    Acta Cardiol Sin; 2019 Nov; 35(6):618-626. PubMed ID: 31879514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.
    Kario K; Mahfoud F; Kandzari DE; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Brar S; Hettrick DA; Fahy M; Böhm M
    Hypertens Res; 2023 Jan; 46(1):280-288. PubMed ID: 36241705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
    Böhm M; Kario K; Kandzari DE; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Konstantinidis D; Choi JW; East C; Lee DP; Ma A; Ewen S; Cohen DL; Wilensky R; Devireddy CM; Lea J; Schmid A; Weil J; Agdirlioglu T; Reedus D; Jefferson BK; Reyes D; D'Souza R; Sharp ASP; Sharif F; Fahy M; DeBruin V; Cohen SA; Brar S; Townsend RR;
    Lancet; 2020 May; 395(10234):1444-1451. PubMed ID: 32234534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Lobo MD; Sharp ASP; Bloch MJ; Basile J; Wang Y; Saxena M; Lurz P; Rader F; Sayer J; Fisher NDL; Fouassier D; Barman NC; Reeve-Stoffer H; McClure C; Kirtane AJ;
    Circulation; 2019 May; 139(22):2542-2553. PubMed ID: 30880441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation.
    Mahfoud F; Townsend RR; Kandzari DE; Kario K; Schmieder RE; Tsioufis K; Pocock S; David S; Patel K; Rao A; Walton A; Bloom JE; Weber T; Suppan M; Lauder L; Cohen SA; McKenna P; Fahy M; Böhm M; Weber MA
    J Am Coll Cardiol; 2021 Jun; 77(23):2909-2919. PubMed ID: 33957242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
    Pathak A; Rudolph UM; Saxena M; Zeller T; Müller-Ehmsen J; Lipsic E; Schmieder RE; Sievert H; Halbach M; Sharif F; Parise H; Fischell TA; Weber MA; Kandzari DE; Mahfoud F
    EuroIntervention; 2023 Sep; 19(7):602-611. PubMed ID: 37427416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Denervation in the treatment of Resistant Hypertension.
    Yap LB; Balachandran K
    Med J Malaysia; 2021 Nov; 76(6):893-897. PubMed ID: 34806679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.